Drug
palcebo
palcebo is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
67%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
2
40%
Phase Distribution
2
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(3)
Terminated(1)
Detailed Status
Completed3
Recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Trials by Status
recruiting120%
completed360%
terminated120%
Recent Activity
1 active trials
Showing 5 of 5
completedphase_2
A Study of HS-20094 in Patients With T2DM
NCT06901648
recruitingphase_1
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
NCT06778850
completedphase_1
Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model
NCT04250363
completedphase_3
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
NCT01638403
terminatedphase_3
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
NCT00626548
Clinical Trials (5)
Showing 5 of 5 trials
NCT06901648Phase 2
A Study of HS-20094 in Patients With T2DM
NCT06778850Phase 1
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
NCT04250363Phase 1
Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model
NCT01638403Phase 3
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
NCT00626548Phase 3
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5